PDCD1 and colorectal carcinoma: As a consequence of the dearth of CRC-specific trial gene expression data available for this study, we employed three previously published predictive gene signatures for anti-PD1 and anti-PDL1 therapies, which had been generated in melanoma, lung and urothelial cancer cohorts (36–38).